Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivarmacitinib Combined With Camrelizumab and Apatinib for uHCC With Acquired Resistance to Immunotherapy
NCT07324473Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
- Start
- Jan 2026
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ivarmacitinib in hepatocellular carcinoma (HCC), sponsored by First Affiliated Hospital of Chongqing Medical University. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
ivarmacitinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07324473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07324473.